FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and deals with application of antibody-CGRP antagonist for prevention and treatment of inflammatory pain. Claimed is application of antibody-CGRP antagonist for obtaining medication for peripheral introduction for prevention and/or treatment of arthritic pain and method of treatment and/or prevention of arthritic pain, which includes peripheral introduction of therapeutically efficient amount of antibody-CGRP antagonist to individual. Also claimed are pharmaceutical composition for peripheral introduction for treatment and/or prevention of arthritic pain, containing antibody-CGRP antagonist and pharmaceutically acceptable carrier, and set, which includes said composition and instruction on application.
EFFECT: group of inventions ensures efficient treatment of arthritic pain with antibody-CGRP antagonist by peripheral introduction, which is more convenient and safe method of medication introduction in comparison with central introduction.
29 cl, 8 dwg, 2 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CHRONIC PAIN | 2009 |
|
RU2522493C2 |
| METHOD OF TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2010 |
|
RU2535074C2 |
| METHODS OF TREATING OR PREVENTING MIGRAINE HEADACHE | 2015 |
|
RU2707745C2 |
| ANTIBODIES AGAINST NERVE GROWTH FACTOR AND METHODS FOR THEIR PRODUCTION AND APPLICATION | 2012 |
|
RU2644235C2 |
| SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2018 |
|
RU2770066C2 |
| CHIMERIC PROTEIN COMPOSED OF NGF ANTAGONIST DOMAIN AND TNFα ANTAGONIST DOMAIN | 2015 |
|
RU2678810C2 |
| OSTEOARTHRITIS TREATMENT | 2009 |
|
RU2712273C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| ANTI-CCR2 ANTIBODIES | 2009 |
|
RU2547595C2 |
